
==== Front
Ann OncolAnn. OncolannoncAnnals of Oncology0923-75341569-8041Oxford University Press 10.1093/annonc/mdz221mdz221CorrigendaDabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study Long G V Flaherty K T Stroyakovskiy D Gogas H Levchenko E de Braud F Larkin J Garbe C Jouary T Hauschild A Chiarion-Sileni V Lebbe C Mandalá M Millward M Arance A Bondarenko I Haanen J B A G Hansson J Utikal J Ferraresi V Mohr P Probachai V Schadendorf D Nathan P Robert C Ribas A Davies M A Lane S R Legos J J Mookerjee B Grob J -J 11 2019 13 8 2019 13 8 2019 30 11 Therapy in breast cancer patients treated in the aTTom trial1848 1848 © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology.2019This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
==== Body
Ann Oncol 2017; 28(7): 1631–1639 (doi: 10.1093/annonc/mdx176)

The following funding information has been added: “This work was supported in part by The University of Texas MD Anderson Cancer Center Support Grant P30 CA016672.”

